Revisiting the role of TRAIL/TRAIL-R in cancer biology and therapy

被引：31

作者：

Singh, Deepika ^{[1
]}

Tewari, Mallika ^{[2
]}

Singh, Sunita ^{[3
]}

Narayan, Gopeshwar ^{[1
]}

机构：

[1] Banaras Hindu Univ, Inst Sci, Dept Mol & Human Genet, Canc Genet Lab, Varanasi 221005, Uttar Pradesh, India

[2] Banaras Hindu Univ, Inst Med Sci, Dept Surg Oncol, Varanasi 221005, Uttar Pradesh, India

[3] Banaras Hindu Univ, Dept Zool, Mahila Mahavidyalaya, Varanasi 221005, Uttar Pradesh, India

来源：

FUTURE ONCOLOGY | 2021年 / 17卷 / 05期

关键词：

apoptosis; cancer therapy; clinical trials; decoy receptors; gene therapy; resistance; death receptors; TNFRSF superfamily; TRAIL; TRAIL-R; APOPTOSIS-INDUCING LIGAND; DEATH RECEPTOR 5; TRAIL-INDUCED APOPTOSIS; CELL LUNG-CANCER; NF-KAPPA-B; DR5; MONOCLONAL-ANTIBODY; UP-REGULATION; IN-VIVO; MEDIATED APOPTOSIS; ANTITUMOR-ACTIVITY;

D O I：

10.2217/fon-2020-0727

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TNF-related apoptosis-inducing ligand (TRAIL), a member of the TNF superfamily, can induce apoptosis in cancer cells, sparing normal cells when bound to its associated death receptors (DR4/DR5). This unique mechanism makes TRAIL a potential anticancer therapeutic agent. However, clinical trials of recombinant TRAIL protein and TRAIL receptor agonist monoclonal antibodies have shown disappointing results due to its short half-life, poor pharmacokinetics and the resistance of the cancer cells. This review summarizes TRAIL-induced apoptotic and survival pathways as well as mechanisms leading to apoptotic resistance. Recent development of methods to overcome cancer cell resistance to TRAIL-induced apoptosis, such as protein modification, combination therapy and TRAIL-based gene therapy, appear promising. We also discuss the challenges and opportunities in the development of TRAIL-based therapies for the treatment of human cancers.

引用

页码：581 / 596

页数：16

共 183 条

[1] Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5 [J].

Adams, C. ;

Totpal, K. ;

Lawrence, D. ;

Marsters, S. ;

Pitti, R. ;

Yee, S. ;

Ross, S. ;

Deforge, L. ;

Koeppen, H. ;

Sagolla, M. ;

Compaan, D. ;

Lowman, H. ;

Hymowitz, S. ;

Ashkenazi, A. .

CELL DEATH AND DIFFERENTIATION, 2008, 15 (04) :751-761

[2] Death Receptor 5 Internalization Is Required for Lysosomal Permeabilization by TRAIL in Malignant Liver Cell Lines [J].

Akazawa, Yuko ;

Mott, Justin L. ;

Bronk, Steven F. ;

Werneburg, Nathan W. ;

Kahraman, Alisan ;

Guicciardi, Maria Eugenia ;

Meng, Xue Wei ;

Kohno, Shigeru ;

Shah, Vijay H. ;

Kaufmann, Scott H. ;

McNiven, Mark A. ;

Gores, Gregory J. .

GASTROENTEROLOGY, 2009, 136 (07) :2365-2376

[3] Discovery and clinical introduction of first-in-class imipridone ONC201 [J].

Allen, Joshua E. ;

Kline, C. Leah B. ;

Prabhu, Varun V. ;

Wagner, Jessica ;

Ishizawa, Jo ;

Madhukar, Neel ;

Lev, Avital ;

Baumeister, Marie ;

Zhou, Lanlan ;

Lulla, Amriti ;

Stogniew, Martin ;

Schalop, Lee ;

Benes, Cyril ;

Kaufman, Howard L. ;

Pottorf, Richard S. ;

Nallaganchu, B. Rao ;

Olson, Gary L. ;

Al-Mulla, Fahd ;

Duvic, Madeleine ;

Wu, Gen Sheng ;

Dicker, David T. ;

Talekar, Mala K. ;

Lim, Bora ;

Elemento, Olivier ;

Oster, Wolfgang ;

Bertino, Joseph ;

Flaherty, Keith ;

Wang, Michael L. ;

Borthakur, Gautam ;

Andreeff, Michael ;

Stein, Mark ;

El-Deiry, Wafik S. .

ONCOTARGET, 2016, 7 (45) :74380-74392

[4] Dual Inactivation of Akt and ERK by TIC10 Signals Foxo3a Nuclear Translocation, TRAIL Gene Induction, and Potent Antitumor Effects [J].

Allen, Joshua E. ;

Krigsfeld, Gabriel ;

Mayes, Patrick A. ;

Patel, Luv ;

Dicker, David T. ;

Patel, Akshal S. ;

Dolloff, Nathan G. ;

Messaris, Evangelos ;

Scata, Kimberly A. ;

Wang, Wenge ;

Zhou, Jun-Ying ;

Wu, Gen Sheng ;

El-Deiry, Wafik S. .

SCIENCE TRANSLATIONAL MEDICINE, 2013, 5 (171)

[5] Regulation of the human TRAIL gene [J].

Allen, Joshua E. ;

El-Deiry, Wafik S. .

CANCER BIOLOGY & THERAPY, 2012, 13 (12) :1143-1151

[6] Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy [J].

Almasan, A ;

Ashkenazi, A .

CYTOKINE & GROWTH FACTOR REVIEWS, 2003, 14 (3-4) :337-348

[7] Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL [J].

Altucci, L ;

Rossin, A ;

Raffelsberger, W ;

Reitmair, A ;

Chomienne, C ;

Gronemeyer, H .

NATURE MEDICINE, 2001, 7 (06) :680-686

[8] Safety and antitumor activity of recombinant soluble Apo2 ligand [J].

Ashkenazi, A ;

Pai, RC ;

Fong, S ;

Leung, S ;

Lawrence, DA ;

Masters, SA ;

Blackie, C ;

Chang, L ;

McMurtrey, AE ;

Hebert, A ;

DeForge, L ;

Koumenis, IL ;

Lewis, D ;

Harris, L ;

Bussiere, J ;

Koeppen, H ;

Shahrokh, Z ;

Schwall, RH .

JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (02) :155-162

[9] Ligand-based targeting of apoptosis in cancer: The potential of recombinant human apoptosis ligand 2/tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL) [J].

Ashkenazi, Avi ;

Holland, Pamela ;

Eckhardt, S. Gail .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (21) :3621-3630

[10] Directing cancer cells to self-destruct with pro-apoptotic receptor agonists [J].

Ashkenazi, Avi .

NATURE REVIEWS DRUG DISCOVERY, 2008, 7 (12) :1001-1012

← 1 2 3 4 5 6 7 8 9 10 →